Interestingly, elevated S100A8/A9 levels predict Venetoclax resistance in acute myeloid leukemia [49], suggesting that modulation of calcium-binding proteins could influence both efficacy and toxicity profiles of BCL2 inhibitors. The gene discussed is BCL2; the disease is acute myeloid leukemia.